🔗 Share this article

While the United States undertakes historic changes to its vaccination recommendations, an unexpected name has emerged somewhat surprisingly: Høeg, an American of Danish descent physician and epidemiologist who first made her name by casting doubt on COVID-19 shots in the pandemic and has zeroed in on alleged deaths after Covid immunization in her short time at the FDA.

Planned Changes to Pediatric Immunization Schedule

Public health authorities had intended to unveil major revisions to the pediatric vaccination calendar in December, synchronizing the US with Denmark’s vaccine program, it is understood – a significant shift that would put the US out of step with a large portion of the world with little proof for improved outcomes. The planned update has been pushed back until the new year.

Rather than the top vaccines chief, Dr. Høeg is set to speak at the event. She was recently named interim head of the FDA’s CDER, the fifth person to lead the division this calendar year.

Consolidating Power at the FDA

The acting appointment could signify a closer partnership between the drug and vaccine divisions as Dr. Høeg and Prasad solidify control at the regulatory agency – and it suggests a greater focus upon rolling back long-standing immunizations at the FDA.

Høeg has often pushed for halting some childhood vaccine recommendations in the US so as to align more in line with Denmark, a society with comprehensive healthcare and a number of inhabitants about the population of Wisconsin’s.

To date public appearances, she has kept her attention on vaccines – typically the purview of Prasad, chief of the FDA’s vaccine center – instead of drug regulation.

Doubts Over Qualifications

The appointee has no apparent background in medication creation, approval processes or management, which has been customary for past leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the commissioner and CBER since March.

“She doesn’t seem to have the necessary background” for running the pharmaceutical oversight division, said Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in running a major agency. She lacks background in drug approvals.”

Past directors of CBER would “grasp laws and regulations and the science of medication creation”, said a former acting FDA commissioner. “Frankly, she doesn’t have the kind of background that former directors who ran the center have had.”

The drug center has an immense range of responsibilities at the FDA, the former commissioner stated.

“Many people just focuses on the novel medication approvals, but the generic program approves a multitude of generic drugs. There is also a biosimilars division, over-the-counter program and more, and each of these have to be supervised,” she said. “The thing you overlook, that is precisely what that I always told people is going to bite you.”

Furthermore, a major administrative element to the job, which supervises over 5,000 employees. “It is a massive administrative position, if you perform it correctly,” Woodcock added.

Agency Reaction and Controversial Initiatives

Regarding inquiries about Dr. Høeg's fitness for the role and whether this appointment signifies greater collaboration among agency officials on vaccines, a press secretary said that the “questions rely on inaccurate assumptions”.

“Her resume aligns with the responsibilities of her job,” the official explained, noting the time Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Høeg inherits the commissioner’s new expedited review system, a contentious expedited therapy clearance system that allegedly concerned her predecessors. “By what process are these therapies being picked for this fast-track system? Who makes the choices?” Dr. Howard questioned. “There’s a lot of secrecy happening at the FDA right now.”

In general, he remarked, “the agency looks to be trending towards laxer oversight of pharmaceuticals, with the exception of shots.”

Public Past Work on Immunizations

Concerning immunizations, Høeg has a more established, if problematic, history, Howard observe. She published a analysis using unverified public submissions to determine the incidence of myocarditis following Covid vaccination. She counseled the state of Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccines are more dangerous than they are.

Included in her “desired changes” for the incoming federal leadership encompassed altering regulations for recently developed shots and discontinuing “unnecessary” immunizations, she remarked post-election on a online show. At the FDA, Dr. Høeg has reportedly floated the idea of preventing young men from getting Covid vaccinations.

“She is an complete dogmatist who begins with her beliefs and tailors the evidence to fit the evidence in a extremely disingenuous, untruthful way,” Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with fellow dissenters, {like|